Certara, Inc. (NASDAQ:CERT) Shares Acquired by Glenmede Trust Co. NA

Glenmede Trust Co. NA raised its holdings in Certara, Inc. (NASDAQ:CERT) by 78.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,206,069 shares of the company’s stock after purchasing an additional 530,598 shares during the quarter. Glenmede Trust Co. NA owned 0.75% of Certara worth $14,123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Blue Trust Inc. purchased a new stake in shares of Certara in the second quarter valued at approximately $26,000. Innealta Capital LLC acquired a new stake in Certara in the second quarter valued at $36,000. KBC Group NV boosted its position in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Certara during the 2nd quarter worth $152,000. Finally, Algert Global LLC purchased a new position in shares of Certara in the 2nd quarter valued at about $156,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Price Performance

CERT stock opened at $11.27 on Friday. The stock’s 50 day moving average price is $10.81 and its 200 day moving average price is $13.07. The firm has a market cap of $1.81 billion, a P/E ratio of -56.35, a PEG ratio of 5.59 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same quarter last year, the company earned $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CERT has been the topic of a number of research analyst reports. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.